ABSTRACT
BACKGROUND: Alveolar bone grafting is known to reduce nasal asymmetry by supporting a defective alar baseand a sunken nostril. However, there are no studies on details of changes in the upper lip with appropriatemeasurements.OBJECTIVE: To measure the change in the upper lip height and nostril sill after alveolar bone grafting.METHODS: Forty-six congenital unilateral cleft lip and alveolus (UCLA) patients (mean age 9.85 years). The patients underwent alveolar bone grafting with autogenous iliac bone grafts. The average bone graft volume was 2.98 cm3.Photographs of the frontal, lateral and basal views were obtained using standardized photographic techniques. The fixedposition points on the patients' faces were measured. Preoperative and postoperative upper lip height and projection, theproportion indexes of the nostril sill were compared.RESULTS AND CONCLUSION: The 6-month follow-up results showed that the height of the upper lip was increased,but no significant difference was found. The projection of the upper lip was more prominent, but there was not statisticallysignificant difference bbetween pre- and post-operation. The nostril sill was significantly elevated in three of four distanceitems. In conclusion, the height of the upper lip is elongated and the nostril sill is elevated after alveolar bone grafting inUCLA patients.
ABSTRACT
Ocular diseases include various anterior and posterior segment diseases. Due to the unique anatomy and physiology of the eye, efficient ocular drug delivery is a great challenge to researchers and pharmacologists. Although there are conventional noninvasive and invasive treatments, such as eye drops, injections and implants, the current treatments either suffer from low bioavailability or severe adverse ocular effects. Alternatively, the emerging nanoscience and nanotechnology are playing an important role in the development of novel strategies for ocular disease therapy. Various active molecules have been designed to associate with nanocarriers to overcome ocular barriers and intimately interact with specific ocular tissues. In this review, we highlight the recent attempts of nanotechnology-based systems for imaging and treating ocular diseases, such as corneal d iseases, glaucoma, retina diseases, and choroid diseases. Although additional work remains, the progress described herein may pave the way to new, highly effective and important ocular nanomedicines.